Aslan Pharmaceuticals . Adr Stock News

HC Wainwright restated their buy rating on shares of ASLAN Pharmaceuticals (NASDAQ:ASLN) in a research note published on Tuesday, AnalystRatings.com reports. Several other research analysts also recently issued reports on ASLN. Zacks Investment Research downgraded shares of ASLAN Pharmaceuticals from a buy rating to a hold rating in a research note on Monday, November 1st. []

ASLAN Pharmaceuticals (NASDAQ:ASLN)s stock had its buy rating reiterated by equities research analysts at HC Wainwright in a note issued to investors on Tuesday, AnalystRatings.com reports. Other analysts also recently issued reports about the company. BTIG Research reiterated a hold rating on shares of ASLAN Pharmaceuticals in a report on Tuesday, October 5th. Zacks Investment [] The post HC Wainwright Reiterates Buy Rating for ASLAN Pharmaceuticals (NASDAQ:ASLN) appeared first on ETF Daily News .

ASLAN Pharmaceuticals (NASDAQ:ASLN)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research report issued on Tuesday, AnalystRatings.com reports. A number of other analysts also recently commented on ASLN. Zacks Investment Research downgraded shares of ASLAN Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, […]

MENLO PARK, Calif. and SINGAPORE, Dec. 06, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of IQVIA Biotech, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, as its preferred clinical research organization for logistics related to decentralized clinical trials, including the global oversight, expansion and engagement of patients for trials related to the clinical development of ASLAN004 and ASLAN003.

Brokerages expect ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) to report earnings per share (EPS) of ($0.15) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for ASLAN Pharmaceuticals earnings, with the lowest EPS estimate coming in at ($0.15) and the highest estimate coming in at ($0.14). ASLAN Pharmaceuticals also reported earnings of ($0.15) per []

MENLO PARK, Calif. and SINGAPORE, Nov. 22, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that Dr Carl Firth, CEO, will be participating in fireside chats at two upcoming virtual health conferences. The details are as follows:

MENLO PARK, Calif. and SINGAPORE, Oct. 14, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatment

The stock price of Aslan Pharmaceuticals Ltd (NASDAQ: ASLN) fell by over 25%. This is why it happened.

ASLAN Pharmaceuticals Ltd (NASDAQ: ASLN) has announced topline data from its Phase 1 study of ASLAN004 for moderate-to-severe atopic dermatitis (AD).  In March 2021, ASLAN announced interim data

- Topline data from multiple-ascending-dose study supports a potentially differentiated safety and efficacy profile

MENLO PARK. Calif. and SINGAPORE, Sept. 21, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatmen

Investors need to pay close attention to ASLAN Pharmaceuticals (ASLN) stock based on the movements in the options market lately.

ASLAN Pharmaceuticals (NASDAQ: ASLN) has closed a secured loan facility provided by K2 HealthVentures (K2HV).  Under the terms of the facility, K2HV will provide ASLAN up to $45 million of secured

An analyst initiates the company's stock with a very bullish note.

ASLN, BLRX, FLXN, ICMB, and MRNS have been added to the Zacks Rank #5 (Strong Sell) List on June 4, 2021.